RecruitingPhase 3NCT06360133

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

A Phase 3, Randomized, Double-Masked, Vehicle-controlled, Multi-center Study Evaluating the Safety and Efficacy of 5% VVN001 in Chinese Subjects With Dry Eye Disease

Sponsor

VivaVision Biotech, Inc

Enrollment

700 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Conditions

Dry Eye

Summary

This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.

Eligibility

Min Age: 30 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VVN001 Ophthalmic Solution, 5% and a drug called VVN001 Ophthalmic Solution, Vehicle for people with dry eye. The study is currently recruiting participants at 1 location. People eligible for this study include aged 30 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVVN001 Ophthalmic Solution, 5%

VVN001 Ophthalmic Solution, 5%

DRUGVVN001 Ophthalmic Solution, Vehicle

VVN001 Ophthalmic Solution, Vehicle

Locations(1)

Eye & Ent Hospital of Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06360133

Related Trials

A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo®

NCT077226241 location

Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye

NCT074131721 location